1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PA-00-029: THE ROLE OF MICROGLIA IN NORMAL AND ABNORMAL IMMUNE RESPONSES OF THE NERVOUS SYSTEM is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH), National Center for Research Resources (NCRR), National Institute on Deafness and other Communicative Disorders (NIDCD), and National Institute on Drug Abuse (NIDA).
This program invites applications to promote research into the role of microglia in the initiation and expansion of autoimmune processes of the central nervous system (CNS) and the resulting injury to CNS components. It aims to intensify interest and investigator-initiated research, attract new investigators, and mobilize interdisciplinary approaches to study microglia's contributions to CNS infections and autoimmunity.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Not explicitly detailed, but invites investigator-initiated research. Confirm the full requirements in the official notice before applying.
PA-00-029: THE ROLE OF MICROGLIA IN NORMAL AND ABNORMAL IMMUNE RESPONSES OF THE NERVOUS SYSTEM is funded by National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH), National Center for Research Resources (NCRR), National Institute on Deafness and other Communicative Disorders (NIDCD), and National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePMHCA (HRSA-26-058) makes $9.79 million available for up to 22 awards of up to $445,000 to build tele-consultation networks that help pediatric primary care providers manage children's behavioral health. The catch buried in the eligibility section: applicants must NOT already hold a PMHCA award — which effectively reserves the new-state lane for the eight unfunded states and territories, plus tribes everywhere. Here's how to read it and what wins.
Read articleTennessee's $206.9M RHTP allocation begins distribution with a 30-day virtual maternal/child mental health consultation grant. The state plans a new opportunity every Friday — the cadence and structure here are the blueprint for how the $50B nationwide program rolls out.
Read article